8-K: Revolution Medicines Reports Strong Daraxonrasib Data in PDAC

Revolution Medicines announced promising clinical data for daraxonrasib in both first-line and second-line metastatic RAS-mutant pancreatic cancer, supporting progression to a Phase 3 trial.

Summary

• Daraxonrasib, a RAS(ON) multi-selective inhibitor, showed updated clinical safety, tolerability, and activity data from its monotherapy Phase 1 RMC-6236-001 study in previously treated metastatic RAS-mutant pancreatic ductal adenocarcinoma (PDAC).
• In second-line (2L+) metastatic RAS-mutant PDAC patients (N=83), 96% experienced any treatment-related adverse events (TRAEs), with 34% experiencing Grade 3 TRAEs. Rash (90%) and GI-related toxicities (diarrhea 52%, nausea 39%, vomiting 36%) were most common.
• For 2L PDAC patients with RAS G12X mutations (N=26), the objective response rate (ORR) was 35%, disease control rate (DCR) was 92%, median progression-free survival (PFS) was 8.5 months, and median overall survival (OS) was 13.1 months.
• For 2L PDAC patients with RAS G12X, G13X, or Q61X mutations (N=38), ORR was 29%, DCR was 95%, median PFS was 8.1 months, and median OS was 15.6 months.
• Initial safety and activity data for daraxonrasib monotherapy in first-line (1L) treatment-naive metastatic RAS-mutant PDAC patients (N=40) showed 95% experienced any TRAE, with 35% experiencing Grade 3 TRAEs. ORR was 47% and DCR was 89% (N=38 efficacy evaluable patients).
• Initial safety and activity data for daraxonrasib (200 mg daily) combined with gemcitabine and nab-paclitaxel (GnP) in 1L metastatic RAS-mutant PDAC patients (N=40) showed 98% experienced any TRAE, with 58% experiencing Grade 3 TRAEs.
• For the 1L combination therapy, ORR was 55% and DCR was 90% (N=31 efficacy evaluable patients).
• The company plans to initiate RASolute 303, a global, randomized Phase 3 trial in 1L metastatic PDAC, evaluating daraxonrasib monotherapy and daraxonrasib plus GnP, compared to a control arm of GnP.

Sentiment

Score: 9

Explanation: The clinical data for daraxonrasib in RAS-mutant PDAC is highly positive, demonstrating strong efficacy (ORR, PFS, OS) in both first-line and second-line settings for a notoriously aggressive and difficult-to-treat cancer. The clear path to a Phase 3 trial for a high-unmet-need indication significantly de-risks the program and indicates strong commercial potential.

Positives

• Daraxonrasib demonstrated notable efficacy in second-line metastatic RAS-mutant PDAC, with an ORR of 35% for G12X mutations and 29% for all RAS mutations, and median OS of 13.1 months and 15.6 months respectively, in a difficult-to-treat population.
• The drug showed strong initial activity in first-line metastatic RAS-mutant PDAC, with a 47% ORR for monotherapy and an impressive 55% ORR when combined with GnP chemotherapy.
• Disease control rates were high across all evaluated groups: 92% (2L G12X), 95% (2L RAS mutant), 89% (1L monotherapy), and 90% (1L combination).
• Despite high rates of any TRAE, dose discontinuation due to TRAEs was relatively low (0% in 2L, 10% in 1L monotherapy, 5% for daraxonrasib in 1L combo), indicating manageable toxicity for many patients.
• The positive preliminary data supports the company's plan to advance daraxonrasib into a global, randomized Phase 3 trial (RASolute 303) for 1L metastatic PDAC, a significant step towards potential market approval.

Negatives

• A high percentage of patients experienced treatment-related adverse events (TRAEs), with 96% in 2L PDAC, 95% in 1L monotherapy, and 98% in 1L combination therapy.
• Grade 3 or higher TRAEs were observed in a significant portion of patients: 34% in 2L PDAC, 35% in 1L monotherapy, and 58% in 1L combination therapy.
• Common TRAEs included rash, stomatitis/mucositis, diarrhea, nausea, and fatigue, which can impact patient quality of life.
• Dose modifications due to TRAEs were frequent, occurring in 48% of 2L patients, 63% of 1L monotherapy patients, and 53% (daraxonrasib) / 55% (GnP) of 1L combination patients.

Risks

• Risks and uncertainties inherent in the drug development process, performing clinical studies, and designing and conducting clinical trials.
• Results of prior clinical trials may not be predictive of future clinical trials, clinical efficacy, or other future results.
• Uncertainties related to regulatory approval processes and the timing of regulatory filings.
• Challenges associated with manufacturing drug products.
• The company's ability to successfully establish, protect, and defend its intellectual property.
• Matters that could affect the sufficiency of the company's capital resources to fund operations.
• Reliance on third parties for manufacturing and development efforts.
• Changes in the competitive landscape impacting the company.
• The effects on the company's business of global events, such as international conflicts or global pandemics.

Future Outlook

The company believes the preliminary data from the RMC-6236-001 and RMC-GI-102 studies support the continued development of daraxonrasib in RAS-mutant PDAC. Revolution Medicines plans to initiate RASolute 303, a global, randomized Phase 3 trial in patients with first-line metastatic PDAC, which will evaluate daraxonrasib monotherapy and its combination with gemcitabine and nab-paclitaxel (GnP) against a GnP control arm.

Management Comments

• Management believes these preliminary data observations from the RMC-6236-001 Study support the continued development of daraxonrasib in patients with RAS-mutant PDAC.
• Management believes these preliminary data observations from the RMC-6236 Study and RMC-GI-102 Study support the company's plans to initiate RASolute 303, a global, randomized Phase 3 trial in patients with 1L metastatic PDAC.

Industry Context

Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and difficult-to-treat cancers, with historically poor prognoses, especially in the metastatic setting. RAS mutations are prevalent in PDAC and have long been considered 'undruggable.' The reported efficacy data for daraxonrasib, particularly the objective response rates and median overall survival in second-line and first-line settings, represent a significant advancement in targeting RAS-mutant PDAC. The move to a Phase 3 trial underscores the potential of this therapy to address a high unmet medical need.

Comparison to Industry Standards

• For second-line metastatic PDAC, treatment options are limited, and median overall survival is typically in the range of 6-9 months. Daraxonrasib's median OS of 13.1-15.6 months in this setting appears to be a substantial improvement.
• In first-line metastatic PDAC, standard chemotherapy regimens like gemcitabine/nab-paclitaxel (GnP) typically yield objective response rates (ORR) of 23-30% and median overall survival of 8-11 months. Daraxonrasib monotherapy's 47% ORR and the combination therapy's 55% ORR significantly exceed these benchmarks, suggesting superior efficacy.
• While FOLFIRINOX offers higher efficacy than GnP in 1L PDAC (ORR ~31-32%, OS ~11 months), it often comes with higher toxicity. Daraxonrasib's combination data, with a 55% ORR, positions it favorably against existing intensive chemotherapy regimens, potentially offering a better efficacy-to-toxicity balance or an alternative for patients unable to tolerate FOLFIRINOX.
• The ability to achieve an ORR of 47% with monotherapy in 1L RAS-mutant PDAC is particularly noteworthy, as targeted therapies for RAS mutations in PDAC have historically been challenging to develop.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results for a key pipeline asset, potentially increasing the company's valuation and future revenue prospects. Progression to Phase 3 is a significant de-risking event.
• Patients with RAS-mutant PDAC: Potential for a new, highly effective treatment option for a cancer with very poor prognosis and limited therapeutic choices, offering improved survival and response rates.
• Healthcare Providers: New treatment option could change standard of care for RAS-mutant PDAC, requiring education and integration into clinical practice.
• Competitors: May face increased competitive pressure in the oncology space, particularly for therapies targeting RAS mutations or pancreatic cancer.

Next Steps

• Initiate RASolute 303, a global, randomized Phase 3 trial in patients with first-line metastatic PDAC.
• The RASolute 303 trial will evaluate daraxonrasib monotherapy, the combination of daraxonrasib plus gemcitabine and nab-paclitaxel (GnP), and a control arm of GnP.

Key Dates

Recommendation

The clinical data presented for daraxonrasib in RAS-mutant pancreatic cancer is exceptionally strong, particularly given the aggressive nature of PDAC and the historical difficulty in targeting RAS mutations. The objective response rates, progression-free survival, and overall survival data, especially in the second-line setting, significantly outperform current standards of care. The decision to proceed directly to a global Phase 3 trial for first-line PDAC further validates the drug's potential and provides a clear, accelerated path to market. This represents a major de-risking event for Revolution Medicines' pipeline and positions the company for substantial future growth in a high-unmet-need oncology market. Investors should view this as a highly positive development with significant upside potential.

Keywords

Revolution Medicines, RVMD, Daraxonrasib, RAS(ON) inhibitor, Pancreatic Ductal Adenocarcinoma, PDAC, RAS-mutant cancer, Oncology, Clinical trial results, Phase 1, RMC-6236-001, RMC-GI-102, RASolute 303, Metastatic cancer, Drug development